miR-10b promotes the motility and proliferation of BC cells via activation of AKT. (A) Fold-changes of miR-10b were assessed in miR-10b transiently overexpressed MCF10A cells. (B) MCF10A cells transiently transfected with miR-10b and treated with or without MK2206 were subjected to wound healing assay (Scale bar, 200 µm) and transwell assay (×100 magnification). (C) Analysis of proliferation of miR-10b transiently overexpressed MCF10A cells cultured ± MK2206 inhibitor. (D) Western blot analysis of E-cadherin, N-cadherin, vimentin, p-AKT and AKT in miR-10b transiently overexpressed MCF10A cells. (E) Western blot analysis of p-AKT and AKT in miR-10b transiently overexpressed MCF10A cells ± MK2206 inhibitor. **P<0.01, ***P<0.001 vs. NC. BC, breast cancer; AKT, protein kinase B; p-AKT, phosphorylated protein kinase B; miR, microRNA; NC, negative control; E, epithelial; N, neural.